Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MBX

MBX Biosciences Inc

Jun 17 • 03:19PM ET

10.11

Dollar change -0.39
Percentage change -3.67	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF VTWO IWO SCHA FESM IWN SBIO IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.20	Insider Own	55.59%	Shs Outstand	33.42M	Perf Week	-11.70%
Market Cap	338.09M	Forward P/E	-	EPS next Y	-2.68	Insider Trans	2.42%	Shs Float	14.84M	Perf Month	-9.36%
Income	-73.47M	PEG	-	EPS next Q	-0.75	Inst Own	54.36%	Short Float	31.98%	Perf Quarter	20.13%
Sales	0.00M	P/S	-	EPS this Y	52.89%	Inst Trans	21.69%	Short Ratio	16.42	Perf Half Y	-50.66%
Book/sh	7.04	P/B	1.44	EPS next Y	2.26%	ROA	-45.74%	Short Interest	4.75M	Perf Year	-
Cash/sh	7.20	P/C	1.40	EPS next 5Y	16.53%	ROE	-48.22%	52W Range	4.81 - 27.50	Perf YTD	-45.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROIC	-31.20%	52W High	-63.22%	Beta	-
Dividend TTM	-	Quick Ratio	23.31	Sales past 5Y	-	Gross Margin	-	52W Low	110.43%	ATR (14)	0.93
Dividend Ex-Date	-	Current Ratio	23.31	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	38.80	Volatility	2.51% 4.63%
Employees	43	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	37.40
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-93.37%	Payout	-	Rel Volume	0.54	Prev Close	10.50
Sales Surprise	-	EPS Surprise	7.79%	Sales Q/Q	-	Earnings	May 12 BMO	Avg Volume	288.98K	Price	10.11
SMA20	-15.23%	SMA50	-2.60%	SMA200	-31.81%	Trades		Volume	141,575	Change	-3.67%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-25	Initiated	Citizens JMP	Mkt Outperform	$38
Oct-08-24	Initiated	Stifel	Buy	$40
Oct-08-24	Initiated	JP Morgan	Overweight	$30
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$44

Jun-16-25 08:00AM	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity (GlobeNewswire)
Jun-10-25 08:00AM	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions (GlobeNewswire)
May-20-25 08:00AM	MBX Biosciences to Participate in June Investor Conferences (GlobeNewswire)
May-15-25 07:16AM	Microbix Reports Results for Q2 Fiscal 2025 (GlobeNewswire)
May-13-25 07:00AM	Microbix & Aurevia Introduce Novel EQA Scheme (GlobeNewswire) -7.81%
08:00AM	Loading…
May-12-25 08:00AM	MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-08-25 07:00AM	Microbix Schedules Release of Results for Q2 Fiscal 2025 (GlobeNewswire) +8.13%
May-05-25 07:00AM	Microbix's Clot-Buster Drug Project Advances (GlobeNewswire)
Apr-22-25 08:00AM	MBX Biosciences to Participate in Citizens and RBC May Investor Conferences (GlobeNewswire) +13.09%
Apr-07-25 08:00AM	MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Mar-26-25 08:00AM	MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-25 08:00AM	MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-05-25 08:00AM	MBX Biosciences Announces Additions to Leadership Team (GlobeNewswire)
Mar-03-25 08:00AM	MBX Biosciences Completes Enrollment in Phase 2 Avail Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism (GlobeNewswire) +5.62%
Feb-18-25 08:00AM	MBX Biosciences to Participate in March Investor Conferences (GlobeNewswire)
08:00AM	Loading…
Jan-23-25 08:00AM	MBX Biosciences to Participate in Upcoming February Investor Conferences (GlobeNewswire) +8.11%
Jan-07-25 11:47AM	MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action (Benzinga) -10.32%
07:00AM	MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia (GlobeNewswire)
Dec-18-24 08:00AM	MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-02-24 08:00AM	MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism (GlobeNewswire) -6.59%
Nov-18-24 08:00AM	MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia (GlobeNewswire) -6.76%
Nov-07-24 08:00AM	MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 08:00AM	MBX Biosciences to Participate in Upcoming November Investor Conferences (GlobeNewswire) -6.50%
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Sep-30-24 08:00AM	MBX Biosciences Presents MBX 2109 Phase 2 Avail Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting (GlobeNewswire) +8.48%
Sep-23-24 07:05PM	Deep Track Capital, LP's Strategic Acquisition in MBX Biosciences Inc (GuruFocus.com)
Sep-18-24 03:19AM	OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc (GuruFocus.com)
Sep-16-24 04:05PM	MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.46%
Sep-12-24 07:11PM	MBX Biosciences Announces Pricing of Initial Public Offering (GlobeNewswire)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pescovitz Ora H.	Director	Apr 08 '25	Buy	5.89	7,693	45,312	24,329	Apr 10 08:39 AM
GORDON CARL L	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:56 PM
GORDON CARL L	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:56 PM
ORBIMED ADVISORS LLC	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:52 PM
ORBIMED ADVISORS LLC	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:52 PM
Hawryluk P. Kent	President & CEO	Feb 04 '25	Buy	10.69	50,000	534,500	448,277	Feb 05 04:17 PM
Mathers Edward T	Director	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:28 PM
BASKETT FOREST	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:26 PM
Behbahani Ali	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:24 PM
Chang Carmen	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:23 PM
Florence Anthony A. Jr.	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:21 PM
Makhzoumi Mohamad	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:20 PM
Walker Paul Edward	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:18 PM
Yang Rick	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:17 PM
SANDELL SCOTT D	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:14 PM
ORBIMED ADVISORS LLC	Director	Sep 16 '24	Buy	16.00	750,000	12,000,000	3,158,428	Sep 17 08:13 PM
New Enterprise Associates 17,	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:12 PM
Frazier Life Sciences X, L.P.	10% Owner	Sep 16 '24	Buy	16.00	625,000	10,000,000	4,552,774	Sep 17 08:11 PM
Heron Patrick J	Director	Sep 16 '24	Buy	16.00	625,000	10,000,000	4,552,774	Sep 17 08:09 PM
Aynechi Tiba	Director	Sep 16 '24	Buy	16.00	750,000	12,000,000	2,136,335	Sep 17 08:05 PM
GORDON CARL L	Director	Sep 16 '24	Buy	16.00	750,000	12,000,000	3,158,428	Sep 17 08:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MBX

MBX Biosciences Inc

Upgrade your FINVIZ experience